{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:07:52Z","timestamp":1780355272232,"version":"3.54.1"},"reference-count":27,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"12","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2023,12,19]]},"DOI":"10.1167\/tvst.12.12.17","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T14:30:59Z","timestamp":1702996259000},"page":"17","source":"Crossref","is-referenced-by-count":10,"title":["Intravitreal Brolucizumab for Pachychoroid Neovasculopathy Associated With Chronic Central Serous Chorioretinopathy"],"prefix":"10.1167","volume":"12","author":[{"given":"Marianna","family":"Carosielli","sequence":"first","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Carnevali","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Magna Gr\u00e6cia, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fallico","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Santa Croce e Carle Hospital, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Chiosi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Azienda Ospedaliera dei Colli-Ospedale Monaldi, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Chronopoulos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ludwigshafen Hospital, Ludwigshafen am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Cucciniello","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Affatato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rapino","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"dell'Omo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Health Sciences \u201cVincenzo Tiberio\u201d, University of Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BROCS study group, BROCS (BROlucizumab for the treatment of Central Serous chorioretinopathy) study group\u2020","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"4","key":"bib1","first-page":"111","article-title":"Pachychoroid diseases of the macula","volume":"3","author":"Gallego-Pinazo","year":"2014","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"4","key":"bib2","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","article-title":"Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy","volume":"126","author":"Mrejen","year":"2019","journal-title":"Ophthalmology"},{"issue":"9","key":"bib3","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","article-title":"Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration","volume":"32","author":"Fung","year":"2012","journal-title":"Retina"},{"issue":"1","key":"bib4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","article-title":"Pachychoroid neovasculopathy","volume":"35","author":"Pang","year":"2015","journal-title":"Retina"},{"issue":"1","key":"bib5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","article-title":"Pachychoroid disease","volume":"33","author":"Cheung","year":"2019","journal-title":"Eye"},{"issue":"5","key":"bib6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ajo.2015.08.009","article-title":"Assessment of choroidal topographic changes by swept-source optical coherence tomography after intravitreal ranibizumab for exudative age-related macular degeneration","volume":"160","author":"Razavi","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"bib7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","article-title":"Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study","volume":"38","author":"Lai","year":"2018","journal-title":"Retina"},{"issue":"12","key":"bib8","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1097\/IAE.0000000000000655","article-title":"Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents","volume":"35","author":"Chhablani","year":"2015","journal-title":"Retina"},{"issue":"1","key":"bib9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","article-title":"Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy","volume":"9","author":"Jung","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"bib10","first-page":"1013","article-title":"Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefe's Archive for","volume":"258","author":"Schworm","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"bib11","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"bib12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"issue":"5","key":"bib13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"issue":"8","key":"bib14","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1167\/iovs.11-7364","article-title":"Diurnal variations in axial length, choroidal thickness, intraocular pressure and ocular biometrics","volume":"52","author":"Chakraborty","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib15","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1167\/iovs.11-8383","article-title":"Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects","volume":"53","author":"Usui","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"bib16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bjophthalmol-2013-304019","article-title":"Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes","volume":"98","author":"Julien","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"bib17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Singlechain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"bib18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"bib19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"bib20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"issue":"7","key":"bib21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","volume":"106","author":"Ogura","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"bib22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajo.2015.04.012","article-title":"Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization","volume":"160","author":"Spaide","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"bib23","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/s41433-019-0511-2","article-title":"Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study","volume":"33","author":"Sacconi","year":"2019","journal-title":"Eye"},{"issue":"2","key":"bib24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/eye.2011.282","article-title":"Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy","volume":"26","author":"Koss","year":"2012","journal-title":"Eye"},{"issue":"6","key":"bib25","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/bjophthalmol-2014-306018","article-title":"A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study","volume":"99","author":"Pitcher","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"bib26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/112067211002000524","article-title":"Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy","volume":"20","author":"Konstantinidis","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"bib27","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2793117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T14:31:04Z","timestamp":1702996264000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2793117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.12.12.17","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}